- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001080
Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals
To ascertain whether the origin of plasma HIV-1-RNA following T cell activation represents the activation of latently infected cells or an increase in cells permissive for replacing viral mutants.
The mechanism by which immune stimulation increases circulating levels of HIV-1 is not known. In particular, it is uncertain whether the transient increase in plasma HIV-1 RNA is due to enhanced replication of an actively replicating pool of HIV-1, or is due instead to activation of proviral sequences in previously resting CD4+ cells. One approach to discriminate these alternatives is a "molecular pulse-chase" experiment. In this approach, drug resistant mutants would be selected by administration of Lamivudine (3TC).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The mechanism by which immune stimulation increases circulating levels of HIV-1 is not known. In particular, it is uncertain whether the transient increase in plasma HIV-1 RNA is due to enhanced replication of an actively replicating pool of HIV-1, or is due instead to activation of proviral sequences in previously resting CD4+ cells. One approach to discriminate these alternatives is a "molecular pulse-chase" experiment. In this approach, drug resistant mutants would be selected by administration of Lamivudine (3TC).
Twenty subjects without prior 3TC experience will be treated with 3TC for 2 weeks. On day 14, half of the subjects will receive immunization with both the influenza and pneumococcal vaccine. 3TC will be discontinued at this time. Patients will be followed for 4 weeks after the immunization.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Antiretroviral therapy, provided the patient has been on the same dose and drugs for 60 days prior to study entry.
Patients must have:
- Documented HIV infection.
- CD4 lymphocyte count of > 300 cells/mm3.
- One plasma HIV-1 RNA level between >= 20,000 and < 120,000 copies/ml.
Prior Medication:
Allowed:
- Stable antiretroviral therapy.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Presence of an AIDS defining opportunistic infection, including Kaposi's sarcoma.
- Allergy to influenza or pneumococcal vaccine or their components; to egg or egg products.
- Unexplained temperature >= 38.5 degrees C for 7 consecutive days within the 30 days prior to study entry.
- Concurrent participation in other experimental therapies.
Concurrent Medication:
Excluded:
- Systemic chemotherapy.
- Steroids.
- Corticosteroids.
- Vaccinations.
- Any new antiretroviral agents that the patient was not taking at the time of study entry and not prescribed by the study.
- Colony stimulating factors including G-CSF or rEPO.
- Immune modulators/immune based therapies.
Concurrent Treatment:
Excluded:
- Radiation therapy.
- Transfusion dependent patients.
Patients with any of the following prior conditions are excluded:
- History of an AIDS defining opportunistic infection, including Kaposi's sarcoma (except limited cutaneous diseases [< 5 lesions]).
- History of acute or chronic pancreatitis.
Prior Medication:
Excluded:
- Prior treatment with 3TC.
Excluded within 30 days of study entry:
- Treatment with immune modulators.
- Acute or chronic therapy for recognized infections (eg, influenza, HSV, VZV).
Excluded within 1 year of study entry:
Treatment with an influenza and/or pneumonia vaccine
[AS PER AMENDMENT 1/23/97:
- influenza vaccine only].
[AS PER AMENDMENT 1/23/97:
- Excluded within 3 years of study entry:
- Pneumonia vaccine.]
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Parallel Assignment
Collaborators and Investigators
Investigators
- Study Chair: Havlir D
- Study Chair: Richman D
- Study Chair: Kuritzkes D
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Immunologic Factors
- Vaccines
- Heptavalent Pneumococcal Conjugate Vaccine
- Lamivudine
Other Study ID Numbers
- ACTG 340
- 11311 (DAIDS ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on Pneumococcal Vaccine, Polyvalent (23-valent)
-
Seema BhatRecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Ab&b Biotechnology Co., Ltd.JSHenan Center for Disease Control and PreventionCompleted
-
National Institute of Allergy and Infectious Diseases...Lederle-Praxis BiologicalsCompletedHIV Infections | Pneumococcal InfectionsUnited States, Puerto Rico
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruiting
-
National Cancer Institute (NCI)Active, not recruitingChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Ann Arbor Stage I Small Lymphocytic Lymphoma | Ann Arbor Stage II Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia... and other conditionsUnited States
-
Merck Sharp & Dohme LLCCompletedHerpes Zoster | Pneumococcal Infection
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedPneumonia, PneumococcalUnited States